Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WIZ | O95785 | 4/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.49 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31334319 | 0.91 | CRBN (0.49) | WIZCRBNIKZF2IKZF1 | |
| SCHEMBL31333591 | 0.87 | IKZF2 (0.63) | IKZF2IKZF1 | |
| SCHEMBL30658467 | 0.87 | IKZF1 (0.58) | WIZCRBNIKZF2IKZF1 | |
| SCHEMBL24819306 | 0.87 | IKZF1 (0.58) | WIZCRBNIKZF2IKZF1 | |
| SCHEMBL22536235 | 0.86 | CRBN (0.51) | WIZCRBNIKZF2CSNK1A1 | |
| SCHEMBL31334533 | 0.86 | CRBN (0.49) | WIZCRBNIKZF2IKZF1CSNK1A1 | |
| SCHEMBL20046226 | 0.86 | CRBN (0.54) | WIZCRBNIKZF2CSNK1A1 | |
| SCHEMBL23705554 | 0.86 | CRBN (0.55) | CRBN | |
| SCHEMBL30273649 | 0.86 | CRBN (0.54) | WIZCRBNIKZF2CSNK1A1 | |
| SCHEMBL29617046 | 0.86 | CRBN (0.55) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3835298-B1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20210221802-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2021118629-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3835298-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | Accutar Biotechnology Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-10800770-B1 | Chroman derivatives having estrogen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800770-B1 | Chroman derivatives having estrogen receptor degradation activity and uses thereof | ESR1, ESR2, ESRRG | WIZ 4668/4885CRBN 280/4885IKZF2 3330/4885 |
| US-20210221802-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESR1, ESRRG | WIZ 4786/4885CRBN 324/4885IKZF2 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.